Why Asthma Clinical Trials Matter More Than Ever
The landscape of asthma treatment in the UK has shifted dramatically in recent years. Where patients once relied solely on inhalers and oral steroids, the NHS now funds a range of biologic therapies — medications derived from living cells that target specific inflammatory pathways. Drugs like mepolizumab, omalizumab, and dupilumab have transformed lives, with some patients reporting they can exercise, travel, and sleep through the night for the first time in decades.
Carly Sylvester, a patient from Jersey, shared her experience after starting mepolizumab injections through Southampton General Hospital. Having lived with asthma since age seven, she described years of escalating symptoms and trying "many different treatments — inhalers, tablets, nebulisers, and steroids" before specialists offered her a biologic. The result? She completed the London Marathon earlier this year. Her story is not unique. Across the UK, patients enrolled in asthma clinical trials and biologic treatment programmes report similar breakthroughs.
Yet access remains uneven. The BEAT-Severe Asthma clinical trials programme, conducted through specialist centres across the UK, found that around 5% of people with asthma have severe disease — characterised by frequent attacks, impaired lung function, and poor symptom control despite high-dose treatments. These individuals are often the best candidates for trials, but many never get referred.
The typical patient profile for UK asthma trials includes adults and adolescents aged 12 and older whose asthma remains uncontrolled on medium-to-high-dose inhaled corticosteroids plus at least one additional controller medication. Some trials focus on specific inflammatory subtypes. The BEAT-Severe Asthma programme, for instance, identified two key groups: those with high eosinophil counts (T2-High, above 300 cells per microlitre) and those with lower eosinophil levels (T2-Low). Each subtype may respond differently to treatments, which is why researchers are increasingly designing trials that match patients to therapies based on their biology rather than a one-size-fits-all approach.
A recent development has been the MHRA approval of depemokimab (branded as Exdensur) — the first ultra-long-acting biologic requiring only twice-yearly dosing for asthma with type 2 inflammation. The SWIFT and ANCHOR phase III trials showed sustained reductions in exacerbations and fewer hospitalisations. For patients who currently manage monthly injections, this represents a significant shift in convenience.
The Different Types of Asthma Trials Recruiting in the UK
Not all asthma trials involve experimental drugs. The UK research ecosystem includes several distinct categories, and understanding these can help patients identify opportunities that match their comfort level.
Drug trials are the most widely recognised. These test new medications — often biologics targeting specific inflammatory pathways — or repurpose existing drugs for asthma. The BEAT-Severe Asthma programme, for example, tested whether doxycycline (a common antibiotic) could reduce attacks in patients with T2-Low asthma, and whether dexpramipexole could help those with T2-High asthma. Some drug trials are first-in-human studies; others, like the depemokimab programme, test medications already approved elsewhere.
Self-management and behavioural trials focus on how patients manage their condition day to day. The IMP2ART programme (IMplementing IMProved Asthma self-management as RouTine), conducted across UK primary care settings, is testing whether structured self-management support delivered in GP practices can reduce asthma attacks and improve quality of life. These trials rarely involve new medications, making them a lower-risk entry point for patients curious about research participation.
Prevention studies target the earliest stages of asthma development. One UK trial is investigating whether house dust mite allergen tablets, given to infants aged 5 to 12 months who have a family history of asthma or allergy, can prevent the development of allergic wheeze — an early indicator of childhood asthma. Studies like this involve NHS paediatric sites and require close monitoring by specialist physicians and nurses.
Mechanistic trials explore the biology of asthma itself. The Cambridge Lung Immune Challenge Study, for example, exposes volunteers to inhaled resiquimod — a compound that mimics viral infection — to study how the immune system responds in people with and without asthma. These studies typically involve smaller participant numbers and more intensive monitoring but provide foundational knowledge for future treatments.
| Trial Category | Example | Typical Duration | Participant Commitment | Potential Benefit | Key Consideration |
|---|
| Drug (Biologic) | Depemokimab SWIFT/ANCHOR | 12–52 weeks | Regular clinic visits, injections | Access to cutting-edge therapy | Possible side effects; placebo arm possible |
| Drug (Repurposed) | BEAT-Severe Asthma (doxycycline) | 12–24 weeks | Oral medication, monitoring visits | Simple treatment regimen | Drug already known; lower novelty |
| Self-management | IMP2ART | 12–18 months | GP practice-based support sessions | Improved daily asthma control | No new medication; routine care setting |
| Prevention | HDM allergen tablets (infants) | 2–5 years | Parent-administered tablets, follow-ups | Reduced asthma risk for child | Long commitment; placebo-controlled |
| Mechanistic | Cambridge R848 challenge | Single exposure | Short, intensive monitoring | Contribution to scientific understanding | No direct therapeutic benefit |
How to Find and Join an Asthma Trial
The path to enrolment starts with a conversation. Most UK asthma trials recruit through specialist respiratory centres at NHS hospitals — Southampton, Leicester, Imperial College London, Manchester, Birmingham, and Cambridge are among the most active sites. Patients under the care of a respiratory consultant are often the first to hear about relevant trials, but self-referral is possible.
The NIHR's "Be Part of Research" platform lists actively recruiting studies across the UK and allows users to filter by condition, location, and trial type. Searching for asthma trials in your postcode area can reveal opportunities that your GP or consultant may not have mentioned. The website includes plain-English summaries, eligibility criteria, and contact details for research teams.
Before you commit, expect a screening process. Researchers assess lung function (usually via spirometry), review medical history, measure blood eosinophil counts, and confirm that current treatments meet the trial's definition of "uncontrolled" asthma. Some trials require a history of two or more exacerbations in the past year. Others may exclude current smokers or people with certain coexisting conditions.
Travel is a practical consideration. Trials based at major teaching hospitals often require regular in-person visits — weekly at the start, then monthly or quarterly. Patients in rural areas or smaller towns may face significant journeys. Some research teams can reimburse travel costs, and a growing number of studies incorporate remote monitoring — using home spirometry devices and smartphone apps to reduce the burden of clinic attendance.
The question of risk understandably dominates many patients' thinking. All UK clinical trials undergo ethics review by the Health Research Authority and are monitored by independent safety committees. Participants can withdraw at any time without affecting their NHS care. Side effects vary by treatment — biologic injections may cause injection-site reactions, while oral medications carry their own profiles. The research team must provide a detailed participant information sheet before you consent, and you should take time to read it.
What patients often find surprising is the level of monitoring involved. Trial participants typically receive more frequent check-ups and lung function tests than they would in routine care. Some describe this as a hidden benefit — catching deterioration early and adjusting treatment promptly.
Making the Decision That Is Right for You
Clinical trials are not for everyone, and that is perfectly reasonable. The time commitment, travel demands, and uncertainty about which treatment arm you will be assigned to (active drug or placebo) are genuine barriers. Some trials are "open-label," meaning all participants receive the active treatment; others are blinded and placebo-controlled, which provides stronger scientific evidence but may mean months on an inactive substance.
For patients whose asthma dominates their life — those who have tried every available NHS treatment without success — trials represent something more than a medical option. They offer agency. The chance to contribute to knowledge that could help others. The possibility, however uncertain, of finding a treatment that finally works.
Speak with your GP or respiratory consultant first. Ask directly: "Are there any clinical trials I might be eligible for?" If the answer is no, check the NIHR Be Part of Research website yourself. Contact the research team for any trial that interests you. The questions you might want to ask include what the time commitment looks like, whether travel costs are covered, what happens if your asthma worsens during the trial, and whether you can continue seeing your usual consultant alongside the study visits.
The UK has some of the most active asthma research centres in the world, and the range of trials recruiting right now — from prevention studies in infants to biologic trials in adults with decades of severe disease — reflects a research community that takes this condition seriously. Whether you participate or not, knowing these options exist is part of being an informed patient.
研究の知恵